Emerging Molecular Approaches in the Analysis of Urine in Bladder Cancer Diagnosis

[1]  T. Ørntoft,et al.  Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. , 2016, European urology.

[2]  D. Serie,et al.  Urinary mRNA biomarker panel for the detection of urothelial carcinoma , 2016, Oncotarget.

[3]  J. Witjes,et al.  Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. , 2016, European journal of cancer.

[4]  Claudia Berrondo,et al.  Expression of the Long Non-Coding RNA HOTAIR Correlates with Disease Progression in Bladder Cancer and Is Contained in Bladder Cancer Patient Urinary Exosomes , 2016, PloS one.

[5]  Z. Cai,et al.  An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese , 2015, Oncotarget.

[6]  S. Selph,et al.  Urinary Biomarkers for Diagnosis of Bladder Cancer , 2015, Annals of Internal Medicine.

[7]  O. Cussenot,et al.  The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. , 2015, Urology.

[8]  Q. Qin,et al.  Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21–1) for bladder cancer: a systematic review and meta-analysis , 2015, Tumor Biology.

[9]  M. Matboli,et al.  Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay , 2015, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  Yu Fan,et al.  Long non‐coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling , 2014, The FEBS journal.

[11]  Peter A. Jones,et al.  A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence , 2014, Clinical Cancer Research.

[12]  Wun-Jae Kim,et al.  Diagnosis of bladder cancer and prediction of survival by urinary metabolomics , 2014, Oncotarget.

[13]  F. Brimo,et al.  The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. , 2014, Annals of diagnostic pathology.

[14]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[15]  M. Shabayek,et al.  Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer , 2013, Pathology & Oncology Research.

[16]  Shahrokh F. Shariat,et al.  Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer , 2014, World Journal of Urology.

[17]  K. Kinzler,et al.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.

[18]  J. Lozano,et al.  Using microRNA profiling in urine samples to develop a non‐invasive test for bladder cancer , 2013, International journal of cancer.

[19]  C. Kwak,et al.  Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[20]  Hester F. Lingsma,et al.  The Use of Molecular Analyses in Voided Urine for the Assessment of Patients with Hematuria , 2013, PloS one.

[21]  Peter A. Jones,et al.  Diagnostic markers of urothelial cancer based on DNA methylation analysis , 2013, BMC Cancer.

[22]  Kohzoh Imai,et al.  Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer. , 2013, European urology.

[23]  Zhongfa Zhang,et al.  The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo , 2013, Clinical Cancer Research.

[24]  H. Feilotter,et al.  A pilot study of urinary microRNA as a biomarker for urothelial cancer. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[25]  Yair Lotan,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. , 2013, European urology.

[26]  D. Hilbert,et al.  Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. , 2012, The Journal of urology.

[27]  T. Ørntoft,et al.  Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation , 2012, PloS one.

[28]  S. Lerner,et al.  Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review , 2012, BJU international.

[29]  D. Silverberg,et al.  Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report , 2012, BMC Urology.

[30]  F. Hamdy,et al.  An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer , 2012, British Journal of Cancer.

[31]  M. Esmat,et al.  Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer. , 2012, Clinical biochemistry.

[32]  A. Osunkoya,et al.  Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. , 2012, International journal of clinical and experimental pathology.

[33]  M. Soloway,et al.  Association of hyaluronic acid family members (HAS1, HAS2, and HYAL‐1) with bladder cancer diagnosis and prognosis , 2011, Cancer.

[34]  Kazuya Kawahara,et al.  MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology , 2011, Cancer science.

[35]  F. Valent,et al.  Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. , 2011, Urologic oncology.

[36]  J. Ku,et al.  Methylation-specific PCR. , 2011, Methods in molecular biology.

[37]  R. Lothe,et al.  Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples , 2010, Clinical Cancer Research.

[38]  M. Babjuk,et al.  Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. , 2010, Urology.

[39]  Hester F. Lingsma,et al.  Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer , 2010, Clinical Cancer Research.

[40]  O. Elashry,et al.  Clusterin as a Diagnostic and Prognostic Marker for Transitional Cell Carcinoma of the Bladder , 2010, Pathology & Oncology Research.

[41]  D. Pode,et al.  The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot study. , 2009, Anticancer research.

[42]  A. Vlahou,et al.  Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics , 2009, Clinical Cancer Research.

[43]  Ewout W Steyerberg,et al.  Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). , 2009, European urology.

[44]  Olivier Cussenot,et al.  Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. , 2008, Urology.

[45]  Yair Lotan,et al.  Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. , 2008, Journal of the National Cancer Institute.

[46]  Yi-wen Liu,et al.  Hyaluronan oligosaccharides are potential stimulators to angiogenesis via RHAMM mediated signal pathway in wound healing. , 2008, Clinical and investigative medicine. Medecine clinique et experimentale.

[47]  Ofer Nativ,et al.  Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. , 2008, The Journal of urology.

[48]  M. Swellam,et al.  Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. , 2007, The Journal of urology.

[49]  H. Moch,et al.  Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis , 2007, International journal of cancer.

[50]  H. Grossman,et al.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. , 2007, The Journal of urology.

[51]  N. K. Sah,et al.  Structural, functional and therapeutic biology of survivin. , 2006, Cancer letters.

[52]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[53]  V. Boddi,et al.  Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. , 2006, The Journal of urology.

[54]  H. Frierson,et al.  Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. , 2006, The Lancet. Oncology.

[55]  E. Zwarthoff,et al.  A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine , 2005, Clinical Cancer Research.

[56]  O. Nanni,et al.  Relevance of urine telomerase in the diagnosis of bladder cancer. , 2005, JAMA.

[57]  D. Landsittel,et al.  Use of the novel marker BLCA-1 for the detection of bladder cancer. , 2005, The Journal of urology.

[58]  M. Rizzo,et al.  Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. , 2005, Oncology reports.

[59]  U. Michl,et al.  Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. , 2004, European urology.

[60]  T. Gasser,et al.  Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. , 2004, The Journal of urology.

[61]  M. Rizzo,et al.  Molecular urinary sediment analysis in patients with transitional cell bladder carcinoma. , 2003, Anticancer research.

[62]  K. To,et al.  Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  R. Day,et al.  Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  N. Block,et al.  HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. , 2000, The Urologic clinics of North America.

[65]  J. Southgate,et al.  Cytokeratin 20 as an objective marker of urothelial dysplasia. , 1996, British journal of urology.